NCT04560231 (RC19LGH) is a EARLY_PHASE1 clinical trial of Remdesivir in SARS-CoV Infection, sponsored by Lahore General Hospital.

Who is sponsoring NCT04560231?

NCT04560231 is sponsored by Lahore General Hospital.

What drugs are being tested in NCT04560231?

Interventions in NCT04560231: Remdesivir.

What condition does NCT04560231 study?

NCT04560231 studies SARS-CoV Infection.

Is NCT04560231 still recruiting?

NCT04560231 is currently status unknown. Last updated 25 September 2020.

Last reviewed 2020-09-25 · How we verify

NCT04560231: RC19LGH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remdesivir in COVID-19 Lahore General Hospital

Status unknown EARLY_PHASE1 Last updated 25 September 2020

What this trial tests

EARLY_PHASE1 trial testing Remdesivir in SARS-CoV Infection in 30 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
30 November 2020

30 November 2020

Quick facts

Lead sponsor	Lahore General Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 June 2020
Primary completion	30 November 2020
Estimated completion	30 November 2020
Sites	1 location across Pakistan

Drugs / interventions tested

Remdesivir (remdesivir) — full drug profile →

Conditions studied

SARS-CoV Infection — all drugs for SARS-CoV Infection →

Sponsor

Lahore General Hospital

Who can join

Adults 15 to 80, any sex, with SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remdesivir is a monophosphoramidate prodrug of an adenosine analogue and it has a broad-spectrum antiviral activity against paramyxoviruses, falviviruses and coronaviruses. It showed in vitro activity on human airway epithelial cells against SARS-CoV-2. It is an investigational drug and granted an Emergency Use Authorization by Food and Drug Administration FDA, so it is under clinical trial. The potent mechanism of action of this drug is still unclear but it effects through several processes. It can interfere with nsp12 polymerase even when exoribonuclease proofreading is intact. It can also produce nucleoside triphosphate NTP that acts pharmacologically active alternate substrate of RNA-chain terminator, as a result NTP can constrain active triphosphates into viral RNA of coronaviruses. There is evidence of high genetic barrier to develop resistance against Remdesivir in coronavirus as a result of which is maintains its effectiveness in antiviral therapies against these viruses. Effectiveness of Remdesivir has been reported against different groups of coronaviruses including Alphacoronavirus NL63 and several SARS/MERS-CoV coronaviruses.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.
Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. · · 2021 · cited 85× · PMID 33549577 · DOI 10.1016/j.ejphar.2021.173926
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population.
Chavda VP, Teli D, Balar PC, Vaghela D, et al · · 2023 · cited 3× · PMID 36903575 · DOI 10.3390/molecules28052332

Verify or expand the search:

Other trials of Remdesivir

Trials testing the same drug.

NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. · Phase 4 · completed
NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) · Phase 3 · terminated

Other recruiting trials for SARS-CoV Infection

Currently open trials in the same condition.

NCT05886816 — Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 · Phase 2 · recruiting
NCT04802408 — SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial · Phase 2, PHASE3 · active not recruiting
NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting
NCT04747522 — Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) · active not recruiting
NCT04579471 — Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study · recruiting

Other Lahore General Hospital trials

Trials by the same sponsor.

NCT07470359 — Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and With · Phase 2 · recruiting
NCT07261306 — Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis · EARLY_PHASE1 · recruiting
NCT07112898 — Effect of Platelet-Rich Plasma on Graft Uptake and Postoperative Outcomes in Full-Thickness Skin Grafting of Face and Ne · NA · enrolling by invitation
NCT07478874 — Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic · NA · completed
NCT07460908 — Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04560231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lahore General Hospital
Last refreshed: 25 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04560231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing